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Abstract
Most cell surface receptors for growth factors and cytokines dimerize in order to mediate signal transduction. For many such
receptors, the Janus kinase (Jak) family of non-receptor protein tyrosine kinases are recruited in pairs and juxtaposed by
dimerized receptor complexes in order to activate one another by trans-phosphorylation. An alternative mechanism for Jak
trans-phosphorylation has been proposed in which the phosphorylated kinase interacts with the Src homology 2 (SH2)
domain of SH2-B, a unique adaptor protein with the capacity to homo-dimerize. Building on a rule-based kinetic modeling
approach that considers the concerted nature and combinatorial complexity of modular protein domain interactions, we
examine these mechanisms in detail, focusing on the growth hormone (GH) receptor/Jak2/SH2-Bb system. The modeling
results suggest that, whereas Jak2-(SH2-Bb)2-Jak2 heterotetramers are scarcely expected to affect Jak2 phosphorylation,
SH2-Bb and dimerized receptors synergistically promote Jak2 trans-activation in the context of intracellular signaling.
Analysis of the results revealed a unique mechanism whereby SH2-B and receptor dimers constitute a bipolar ‘clamp’ that
stabilizes the active configuration of two Jak2 molecules in the same macro-complex.
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Introduction
Non-receptor protein tyrosine kinases of the Janus kinase (Jak)
family play an essential role in signal transduction mediated by a
host of cell surface receptors that lack intrinsic enzymatic activity.
As a prominent example, the receptor for growth hormone (GH),
a therapeutically important cytokine that modulates an array of
cellular processes, including metabolism, proliferation, and
survival [1], constitutively associates with intracellular Jak2 [2–
4]. The ordered binding of the bivalent GH ligand results in the
formation of active cell surface complexes comprised of one GH
and two receptor molecules, a process that is understood in
exquisite mechanistic detail [5]. The dimerized receptors juxta-
pose two associated Jak2 molecules, facilitating transphosphoryla-
tion of both Jak2 and the receptor [2]. Phosphorylation of Jak2
further activates the enzyme, and receptor phosphorylation sites
foster recruitment of the signal transducer and activator of
transcription (STAT) variants STAT3 and STAT5b, which are
phosphorylated by Jak2 [6].
Given the central role of Jak2 in GH receptor signaling, it is not
surprising that its function is modulated by other proteins. A
prominent negative regulator is suppressor of cytokine signaling
(SOCS)-1, which binds phosphorylated Tyr
1007 in the activation
loop of Jak2 and elicits degradation of the kinase [7,8]. Conversely,
the ubiquitously expressed adaptor protein SH2-Bb also binds
Jak2 but instead enhances its function [9–12]. The core structure
of SH2-Bb contains an N-terminal dimerization domain (DD), a
pleckstrin homology (PH) domain, and a C-terminal Src
homology-2 (SH2) domain. Among the multiple Jak2 sites
phosphorylated in response to GH stimulation, Tyr
813 is
specifically recognized by the SH2-Bb SH2 domain [13]. SH2-B
also dimerizes by homotypic association of the DD, which has led
to a conceptual model in which SH2-Bb facilitates Jak2 autopho-
sphorylation through formation of a heterotetrameric Jak2-(SH2-
Bb)2-Jak2 complex [14]. In support of this mechanism, purified
SH2-Bb enhances Jak2 phosphorylation in solution with a
biphasic dose response, consistent with saturation of Jak2 at high
SH2-Bb concentrations to form dead-end Jak2-(SH2-Bb)2 com-
plexes; in the same study, it was further shown that either the SH2
domain or DD expressed alone can antagonize GH-stimulated
Jak2 and STAT5b phosphorylation in cells [14]. There is also
evidence to the contrary, as the SH2 domain of SH2-Bb was
sufficient to activate Jak2 in a different experimental context
[15,16]; if so, the biphasic dependence of Jak2 autophosphoryla-
tion on SH2-Bb concentration might be attributed to a second,
inhibitory interaction involving the PH domain. Although the PH
domain has not yet been characterized fully, it has a speculated
role in targeting SH2-Bb to the plasma membrane, based on the
established interactions of other PH domains with specific
phosphoinositide lipids. Clearly, the two proposed mechanisms
of SH2-Bb function highlighted here present opposing views
regarding the importance of DD dimerization.
In this work, we apply computational modeling to critically
analyze the role of SH2-Bb in Jak2 activation, revealing a novel
mechanism. The model accounts for GH/GH receptor dynamics
and Jak2/GH receptor, SH2/Jak2, DD/DD, and PH/lipid
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domain-based models of Shp2 [17] and phosphoinositide 3-kinase
regulatory subunit [18], this small number of interactions can
produce thousands of distinct molecular species, and we manage
this combinatorial complexity using the rule-based modeling
approach [19]. Whereas our results challenge the notion that SH2-
Bb dimerization is sufficient for significant Jak2 association in
solution or in cytosol, they also show that SH2-Bb can significantly
enhance Jak2 activation stimulated by GH. Dimerized receptors
on the one hand, and dimerized SH2-B on the other, are proposed
to act as a bipolar clamp that promotes Jak2 transphosphorylation
by holding two Jak2 molecules in the same complex (Figure 1, top
right).
Results
Jak2-SH2-Bb heterotetramerization is an inefficient
mechanism for promoting Jak2 autophosphorylation in
vitro
Nishi et al. [14] purified Jak2 and SH2-Bb and showed that
SH2-Bb enhances Jak2 autophosphorylation in solution. They
obtained results with 14 pM Jak2 and SH2-Bb concentrations in
the range of 0.01–100 nM, which were incubated along with
excess ATP for 10 minutes at 25uC in a total volume of 150 mL.
The greatest change in Jak2 phosphorylation was seen as the SH2-
Bb concentration increased from 0.1 to 1 nM, and the effect of
SH2-Bb decreased at higher concentrations [14]. We recapitulat-
ed those conditions in our In Vitro Model (Methods), with the
affinities of the SH2-Bb (SH2)/Jak2 and SH2-Bb dimerization
(DD/DD) interactions varied systematically (Figure 2). The SH2
domain affinity, characterized by KD,JS, was assigned values in the
range of 1–100 nM, which are at the low end of KD values (high
affinity) measured for single SH2 domains [20,21]. Indeed,
although the KD of the interaction between full-length SH2-Bb
and Jak2 is not known, the isolated SH2 domain binds to a Jak2-
derived phospho-peptide with KD=80–550 nM [22,23]. For DD
dimerization, we considered an even wider range of KD,SS values,
from 0.1 nM to 10 mM. Because there are no phosphatases
present, the dephosphorylation reactions are turned off in the In
Vitro Model, and as a best-case scenario, we assume that the SH2-
Bb binding site of Jak2 (Tyr
813, or Y1) is pre-phosphorylated. In
this context, phosphorylation of the Jak2 activation site (Tyr
1007,
or Y2) is the readout of the model, which serves as a surrogate for
the modification of multiple Jak2 autophosphorylation sites.
The results show that, if Jak2 autophosphorylation were to
proceed by the proposed heterotetramer (JS2J) formation
mechanism, the extent of phosphorylation is at most ,0.3%, or
,0.01 fmol, of Jak2 (Figure 2A–C). Analysis of the model indicates
that the rate of phosphorylation is limited by the rate of exchange
between phosphorylated and unphosphorylated Jak2 in the hetero-
tetrameric complex, which is most affected by the rate of Jak2-SH2-
Bb association.The valuesoftheassociation rateconstants,kon,JSand
kon,SS,arefixedat0.06 nM
21 min
21 (1 mM
21 s
21)inthemodel,and
therefore similar levels of Jak2 phosphorylation are predicted over
multiple decades of KD (koff) values.
These results are difficult to reconcile with the experimental
observations for the following reasons. First, to produce optimal
phosphorylation at SH2-Bb concentrations of ,1–10 nM, ex-
tremely high-affinity interactions are required for both the SH2
domain and DD of SH2-Bb (KD values ,1 nM). Second, the
predicted amount of phosphorylated Jak2 is probably too low to be
detected by immunoblotting. Even if it were 10-fold higher, as by
assuming kon=10mM
21 s
21 (quite high for protein-protein
interactions), it is unclear whether or not it would be detectable.
The in vitro role of SH2-Bb dimerization is even more difficult to
reconcile if we relax the assumption that the SH2-Bb binding site
(Y1) is pre-phosphorylated. Indeed, an alternative model was
considered that includes SH2-Bb-independent Jak2 dimerization
and phosphorylation of Y1 as a prerequisite for SH2-Bb binding,
and we found that very high concentrations of SH2-Bb
Figure 1. Molecular species and interactions considered in our
models. Three models of increasing complexity were formulated and
analyzed, as described under Methods. The In Vitro Model considers the
enhancement of Jak2 (J) autophosphorylation by SH2-Bb (S) in solution
and includes 11 species (dashed triangle). Two Jak2 phosphorylation
sites are considered: Y1, which when phosphorylated (Y1,P) engages
SH2-Bb, and Y2, which when phosphorylated (Y2,P) enhances the
kinase activity. The model considers the best-case scenario where Y1 is
constitutively (or rapidly) phosphorylated. The Simplified Cellular Model
includes GH ligand (L) and GH receptor (R) and also considers Jak2
species with Y1 dephosphorylated in the cytosol (dashed square). In this
model, Jak2 binds constitutively to receptors, but binding of two Jak2
molecules in the same complex is required for Jak2 autophosphoryla-
tion. Finally, the Extended Cellular Model additionally considers
phosphoinositide (P) lipids, which mediate localization of SH2-Bb to
the plasma membrane. The complex shown in the upper right depicts
the ‘bipolar clamp’ mechanism whereby SH2-Bb stabilizes macro-
complexes containing two Jak2 molecules.
doi:10.1371/journal.pcbi.1000364.g001
Author Summary
Janus kinases (Jaks) interact with and activate receptors on
the cell surface that mediate changes in gene expression.
How these interactions are promoted and regulated is of
central interest in fields such as cellular endocrinology and
immunology. Here, detailed computational models of Jak
activation are offered at the level of protein modification
states and interaction domains, wherein the specification
of only a handful of binding/reaction rules can produce
networks comprised of thousands of differential equations.
Specifically, we investigated the role of an adaptor protein,
SH2-B, revealing a novel mechanism whereby it cooper-
ates with receptors to form a stable complex that
juxtaposes two Jak molecules for efficient activation. We
refer to this mode of molecular assembly as the bipolar
clamp mechanism.
Rule-Based Model of Jak2 Activation
PLoS Computational Biology | www.ploscompbiol.org 2 April 2009 | Volume 5 | Issue 4 | e1000364(&100 nM) are needed to enhance Jak2 phosphorylation, even
when the binding affinities are arbitrarily high; even then, the
magnitude of the enhancement is quite small (Figure S1,
Supporting Information). In that model, SH2-Bb must associate
rapidly with Jak2 dimers that happen to have catalyzed the
phosphorylation of Y1 on both Jak2 molecules, but not of the
activating site, Y2; Y2 phosphorylation on either Jak2 molecule
leads to rapid phosphorylation of available sites, in which case
SH2-Bb binding has no bearing on the Jak2 phosphorylation
status of that complex. With a total Jak2 concentration of 14 pM,
the overall concentration of monomeric Jak2 with Y1 phosphor-
ylated never achieves an appreciable concentration for dimeriza-
tion of Jak2/SH2-Bb complexes in solution.
Based on this analysis, the formation of JS2J heterotetramers
cannot adequately explain how SH2-Bb apparently enhances Jak2
phosphorylation in this assay. The aforementioned alternative
mechanism, whereby SH2-Bb binding stabilizes Jak2 in a more
active conformation [16], is more plausible in the context of Jak2
autophosphorylation in solution. In the rest of this paper, we focus
on the more pertinent question of how SH2-Bb dimerization
might enhance Jak2 phosphorylation in cells.
SH2-Bb dimerization significantly enhances Jak2
autophosphorylation in the cellular context by
coordinating Jak2/GH receptor binding: The bipolar
clamp mechanism
Whereas it seems unlikely that SH2-Bb-mediated heterotetra-
mers could form to a significant extent in solution to explain the
activation of Jak2 in vitro, Jak2 kinase activity is normally associated
with cytokine receptor signaling at the plasma membrane in vivo.
Using our Simplified Cellular Model (Methods), we quantified
activated (receptor-bound and Y2-phosphorylated) Jak2 stimulat-
ed by varying doses of GH at steady state, relative to the number
of cell-surface GH receptors in the absence of GH (Figure 3); as
explained previously [24], maximal GH receptor activation is
accompanied by significant downregulation from the surface, so a
relative value of ,0.05 by this measure is the maximum. The
Simplified Cellular Model does not allow for membrane
localization of SH2-Bb through its PH domain.
In the absence of SH2-Bb, or (equivalently) with SH2-Bb
lacking the DD, the Jak2/receptor binding may be estimated in a
straightforward manner. For the parameter values assumed, with
total Jak2 expression in excess over receptors and equal to the KD
of Jak2/receptor binding, roughly half of the dimerized receptors
are bound with Jak2, and so roughly 1/4 of the receptor dimers
have two Jak2 molecules bound and phosphorylated at steady state
(Figure 3A). It is noted that, for the parameter values assumed, the
two Jak2 molecules remain almost fully phosphorylated on Y1 and
Y2 while in the same receptor complex; therefore, allowing SH2-
Bb binding to further enhance Jak2 catalytic activity [16] is of little
consequence in this context (Figure S2A, Supporting Information).
By comparison, the presence of dimerization-competent SH2-Bb
(with the reasonable assumption that STot=JTot=KD,JS=KD,SS)
increases by ,3-fold the number of receptor dimers with two Jak2
bound (Figure 3A) and, accordingly, the number of Jak2 molecules
with Y2 phosphorylated (Figure 3B). Analysis of the model shows
that it does so by forming stable, seven-member ‘‘macro-
complexes’’ containing GH, two receptor, two Jak2, and two
Figure 2. Critical analysis of the SH2-Bb-mediated Jak2 autophosphorylation mechanism in vitro. (A–C) Surface and contour plots of Jak2
autophosphorylation (Y2,P) for varying concentrations and dimerization KD values of SH2-Bb, and with three different KD values of Jak2/SH2-Bb
binding: (A) KD,JS=100 nM; (B) KD,JS=10 nM; (C) KD,JS=1 nM. See text for a description of the model assumptions, following [14]. (D) Surface and
contour plot of heterotetramer (JS2J) concentration for KD,JS=1 nM.
doi:10.1371/journal.pcbi.1000364.g002
Rule-Based Model of Jak2 Activation
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dimerized receptors serve as a template for Jak2 recruitment, and,
once Jak2 has been autophosphorylated, the SH2-Bb dimer
clamps the active Jak2 molecules in place.
To further characterize this hypothetical mechanism, the
intracellular concentration and dimerization affinity of SH2-Bb
were varied for a constant GH concentration of 10 nM (Figure 4).
Although a broad range of SH2-Bb concentrations was tested in
order to evaluate the full spectrum of behaviors, it is noted that the
endogenous SH2-Bb expression level is not expected to be above
the nanomolar range. Given a constant Jak2/SH2-Bb affinity
(KD,JS=100 nM), the SH2-Bb concentration should be of a similar
magnitude or somewhat higher for near maximal enhancement of
Jak2 phosphorylation; extremely high SH2-Bb concentrations,
similar in magnitude to xr (100 mM; see Methods) are needed to
antagonize the formation of the stable macro-complex, leading
instead to formation of less stable, nine-member S2J(RLR)JS2
complexes (Figure 4A). Analysis of the GH receptor/Jak2
complexes formed reveals that, as expected, SH2-Bb stabilizes
complexes with two Jak2 molecules while increasing the total Jak2
recruitment only modestly (Figure 4B). In the absence of SH2-Bb,
approximately half of all GH receptors are Jak2-bound, and this
constitutive binding accounts for a significant fraction of the total
at all SH2-Bb concentrations.
Membrane localization of SH2-Bb via its PH domain
broadens Jak2 activation potency, but SH2-Bb
dimerization is still essential
We next considered the role of the SH2-Bb PH domain, which
is thought to mediate binding with phosphoinositides and thus
plasma membrane localization [25], in our Extended Cellular
Model (Figure 5). Based on physical principles, membrane
localization increases the rate of association between complexes
containing receptor or/and phosphoinositide molecules by
roughly two orders of magnitude, enhancing the binding of
SH2-Bb with receptor-bound Jak2 (Methods). In fact, we find that
the addition of the PH domain interaction broadens the efficacy of
SH2-Bb-mediated Jak2 activation down to low nanomolar SH2-
Bb concentrations, well below the assumed KD of the Jak2/SH2-
Bb interaction in solution (Figure 5A). As in the Simplified Cellular
Figure 3. SH2-Bb significantly enhances GH receptor-mediated Jak2 autophosphorylation in vivo. Steady-state calculations were
performed using the Simplified Cellular Model, with equal Jak2 and SH2-Bb concentrations and KD values (JTot=STot=KD,JS=KD,SS=100 nM). In the
SH2-B null case, STot=0, and in the DD-mutated SH2-B case, KD,SS=infinity; these two cases are functionally equivalent (and therefore the curves lie on
top of one another). (A) SH2-Bb does not affect GH dose-dependent receptor-dimerization (all of the filled symbols in panel A lie approximately on
top of one another) but mediates ,3-fold improvement in pair-wise recruitment of Jak2 to receptors (the number of Jak2 molecules engaged in
receptor-Jak2 complexes containing two Jak2). (B) Accordingly, SH2-Bb enhances Jak2 autophosphorylation (site Y2) by roughly 3-fold.
doi:10.1371/journal.pcbi.1000364.g003
Figure 4. SH2-Bb dimerization coordinates the formation of macro-complexes containing two Jak2 molecules bound to GH-
dimerized receptors. Steady-state calculations were performed using the Simplified Cellular Model and the same parameter values as in Figure 3,
except with 10 nM GH stimulation and varying SH2-Bb concentration. (A) Receptor-bound, phosphorylated Jak2 (Y2,P), for various values of the
SH2-Bb dimerization affinity. The extreme cases of KD,SS equal to zero and infinity correspond to irreversible and no dimerization, respectively;
intermediate KD,SS values are 10 nM, 100 nM, 1 mM, and 10 mM. (B) Analysis of receptor/Jak2 complexes, with KD,SS=100 nM. SH2-Bb dimerization
coordinates the binding of two Jak2 molecules to dimerized receptors, while affecting overall receptor/Jak2 binding only modestly. Complexes
containing more than two Jak2 molecules (e.g., J(RLR)JS2J) are rare.
doi:10.1371/journal.pcbi.1000364.g004
Rule-Based Model of Jak2 Activation
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overall Jak2/receptor binding (Figure 5B). Membrane localization
of SH2-Bb facilitates binding to receptor-bound Jak2 and SH2-Bb
dimerization, and therefore it stabilizes signaling-competent
macro-complexes at the expense of other receptor/Jak2 complexes.
To probe this mechanism further, we repeated the analysis with
the DD of SH2-Bb removed. Intuitively, one might expect that
membrane localization of SH2-Bb would drive significantly more
Jak2 into complex with receptors; however, this was not the case
with the DD present (Figure 5B), and accordingly, Jak2 autopho-
sphorylation was not dramatically enhanced by SH2-Bb with the
DD absent, even with arbitrarily high SH2-Bb and phosphoino-
sitide concentrations (Figure 5C and 5D). Variation of the other
parameters, such as the Jak2 concentration and binding affinities,
did not qualitatively affect the outcome (results not shown).
Why is SH2-Bb dimerization predicted to be so important in
the cellular context? A key insight is that Jak2 must be
phosphorylated on Y1, by associating with dimerized receptors,
before it can bind membrane-localized SH2-Bb. Phosphorylated
Jak2 might even associate with SH2-Bb quite readily, but the
lifetime of the receptor/Jak2 interaction is not affected as a result.
The association of JSP complexes with free receptors is modest
because this pool of Jak2 is small; once formed, the JSP complex is
more likely to dissociate via one of its two linkages than to associate
with a free receptor site, and when it does bind free receptors, it
does not discriminate between dimerized and inactive receptor
molecules. By comparison, SH2-Bb dimerization specifically
stabilizes Jak2 interactions with dimerized receptors; this is the
essence of the bipolar clamp mechanism.
Predictions regarding the potency of SH2-Bb mutants as
dominant-negative inhibitors of GH receptor signaling
To further evaluate the roles of the functional SH2-Bb domains,
we assessed the ability of different domain mutants to antagonize
the function of wild-type SH2-Bb in cells, i.e., to act as a dominant
negative (Figure 6). The Extended Cellular Model was used with
the addition of the mutant SH2-Bb species. The SH2 domain
alone competes with wild-type for Jak2 binding and is an effective
inhibitor at concentrations of at least 1 mM (for nanomolar
concentrations of endogenous SH2-Bb, as expected), which is 10-
fold higher than the assumed value of KD,JS (Figure 6A). Inhibition
by the DD alone is through dimerization with wild-type SH2-Bb
and is somewhat less effective (Figure 6B), which might be
attributed to the partial neutralization of the DD through homo-
dimerization. The addition of the PH domain to either the SH2
domain (functionally equivalent to the DD-mutated SH2-B
analyzed in Figure 5C and 5D) or the DD results in membrane
localization of the mutant SH2-Bb and, accordingly, more potent
disruption of receptor/Jak2/SH2-Bb macro-complexes when it is
expressed in excess compared with wild-type SH2-Bb; comparing
PH-SH2 and DD-PH, the former construct shows the more robust
inhibition of SH2-Bb function (Figure 6C and 6D). The predicted
efficacies of these two dominant-negatives reflect the gamut of
effects, both strong and subtle, discussed previously: 1) the effect of
SH2-Bb concentration, relative to its Jak2-binding affinity, on
macro-complex formation; 2) antagonism of macro-complex
formation at extreme SH2-Bb concentrations, exceeding the value
of xr; and 3) the ability of phosphoinositides to enhance the
effective concentration of SH2-Bb, which facilitates macro-complex
Figure 5. Membrane localization and dimerization of SH2-Bb synergize to enhance the potency of its Jak2 activation-promoting
function. Steady-state calculations were performed using the Extended Cellular Model and the same parameter values as in Figure 4B. The total
concentration of phosphoinositide, on a whole-cell basis, is either 0, 100 nM, or 1 mM as indicated, and its recruitment of SH2-Bb PH domain is
characterized by KD,SP=100 nM. Two scenarios are considered: full-length SH2-Bb (A and B) and SH2-Bb with the dimerization domain absent (C and
D). The calculated quantities are receptor-bound, phosphorylated Jak2 (Y2,P; A and C) and total receptor-bound Jak2 (B and D).
doi:10.1371/journal.pcbi.1000364.g005
Rule-Based Model of Jak2 Activation
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Jak2-receptor association at high SH2-Bb concentrations that is
independent of SH2-Bb dimerization.
Discussion
This is the third system we have studied using the rule-based
modeling approach to specifically address the concerted binding of
multiple, modular domains in signaling proteins. This aspect of
signal transduction is a recognized source of complexity in the
signal transduction field [26,27], yet it is commonly side-stepped in
the formulation of mathematical models of signaling pathways. At
the level of pathways and networks, we recognize and espouse that
the finer molecular details, while important to consider, must be
simplified (or ‘‘lumped’’, in the mathematical sense). The rule-
based approach addresses the problem of combinatorial complex-
ity [28], its main strength being that it allows the modeler to
invoke more mechanistic or biologically plausible assumptions
[29]; however, it cannot ease the burden associated with specifying
a large number of model parameters, which becomes increasingly
problematic at the pathway/network level. For this reason, we
apply rule-based modeling to subsystems that involve only a
handful of interactions yet give rise to combinations of complexes
that could not readily be enumerated in the classical way. Indeed,
in this work, models with as many as 3,821 differential equations
were generated. Despite their large size and complex structure,
these models were generated with a small number of generating
equations (‘‘rules’’) and are governed by only a handful of
parameters.
We analyzed the receptor-mediated activation of Jak2 and the
role of the adaptor protein SH2-Bb, which contains three modular
domains (DD, PH, and SH2), and demonstrated how modeling
can be used to evaluate the integration of domain functions as they
affect receptor-mediated signaling in cells. In particular, we sought
to clarify the role of SH2-Bb dimerization. Protein homodimer-
ization, or dimerization of structurally homologous proteins, is a
ubiquitous process in molecular biology and permeates signal
transduction from the receptor level (e.g., cytokine receptors,
receptor tyrosine kinases) to the activation of transcription factors
(e.g., STATs, Smads). Ligand-induced dimerization of the GH
receptor is necessary but not sufficient for intracellular signaling,
requiring also the juxtaposition of two Jak2 molecules; this theme
is common to (and our conclusions are predicted to be applicable
to) signaling mediated by dimers of the closely-related erythro-
poietin receptor [30]. Dimerization of SH2-B isoforms, and of the
closely related APS proteins, is unique because they are considered
adaptors or modulators of, not executors of, intracellular signaling.
Our results suggest that dimerization of SH2-B goes hand in
hand with the binding of Jak2 to dimerized receptors, which
template the assembly of the JS2J heterotetrameric unit. Thus,
dimerized receptors and SH2-Bb together coordinate the
recruitment of two Jak2 molecules. At least in the context of our
models, it is incorrect to characterize SH2-Bb dimerization as a
means of bringing two Jak2 molecules together, as might be
inferred by the ability of the adaptor to enhance Jak2 autopho-
sphorylation in solution; rather, we suggest that it acts as a clamp
that stabilizes existing J(RLR)J complexes. This is because Jak2
must already be autophosphorylated, at least on Tyr
813, for SH2-
Bb to bind. Accordingly, enhancing the association rates of the
RJ/S or R/JS linkages, as by membrane localization of SH2-Bb,i s
insufficient for significant enhancement of Jak2 phosphorylation if
SH2-Bb cannot dimerize.
Figure 6. Potencies of SH2B-b domain mutants as dominant negatives antagonizing wild-type SH2-Bb function. Jak2 phosphorylation
was calculated using the Extended Cellular Model as in Figure 5A, with the same parameter values and PTot=1mM. To this model, we added one of
the following SH2-Bb constructs: SH2 only (A), DD only (B), PH-SH2 (C), and DD-PH (D). As indicated, the value of the overall inhibitor concentration
was either 0 (no inhibition; same as Figure 5A), 100 nM, 1 mM, or 10 mM.
doi:10.1371/journal.pcbi.1000364.g006
Rule-Based Model of Jak2 Activation
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concerns the mechanism by which SH2-Bb dimerization affects
Jak2 autophosphorylation, as outlined above. We anticipate that
testing the bipolar clamp mechanism concept would be a
challenge, because for any mechanism involving SH2-Bb,
enhancement of GH-stimulated Jak2 phosphorylation hinges upon
Jak2 binding to GH receptors and its subsequent phosphorylation
on Tyr
813. In principle, however, one could express the following
Jak2 mutants in cells, in parallel experiments: 1) a phosphoryla-
tion-mimicked (Y813D) Jak2 mutant, 2) a phosphorylation-
deficient (Y813F) Jak2 mutant, and 3) a variant of mutant 1 that
cannot interact with GH receptor. If over-expressed at a level that
is sufficient to saturate constitutive binding to GH receptors, where
applicable, then cells expressing mutant 1 or mutant 2 (or wild-
type Jak2) would be expected to show similar levels of GH-
stimulated autophosphorylation, greater than those expressing
mutant 3, because the stabilizing effect of SH2-Bb would be
superfluous. In contrast, if mutant 1 and mutant 2 were co-
expressed in cells at similar levels, SH2-Bb should stabilize mutant
1 (or wild-type Jak2) relative to mutant 2, which would be reflected
by their differential autophosphorylation.
Other predictions consider the potential role of the SH2-Bb PH
domain (or whichever structural motif is responsible for the
observed membrane localization). In a cellular context where
endogenous SH2-Bb expression is lacking or repressed, compar-
ison of wild-type SH2-Bb and a mutant defective in lipid binding
might only show moderate differences, and in fact the mutant
might outperform the wild-type adaptor if the adaptor concentra-
tion is in the high nanomolar range (as is often the case for
expression plasmids; Figure 5). The model results suggest that the
role of membrane localization is to broaden the efficacy of SH2-
Bb to low or sub-nanomolar concentrations of the adaptor. But by
the same token, we show that membrane localization of SH2-Bb
should enhance the inhibitory properties of constructs that lack
either the SH2 domain or the DD, and thus the importance of the
membrane localization effect might be more effectively interro-
gated through such inhibition experiments. To put these
predictions in the proper context, it will be important to identify
the sequence(s) of SH2B-b responsible for its apparent membrane
localization, whether in the PH domain or elsewhere in the
molecule.
Besides the bipolar clamp mechanism explored here, it has also
been postulated that SH2-Bb binding is sufficient for enhancing
Jak2 catalytic efficiency [16], and this alternative mechanism
might account for the apparent ability of SH2-Bb to enhance Jak2
autophosphorylation in solution and in unstimulated cells (with
Jak2 overexpressed) [14]. This alternative mechanism might also
complement the bipolar clamp function of SH2-Bb, but only in
cells where Jak2 in J(RLR)J complexes (without SH2-Bb bound)
tends to be dephosphorylated, at least on certain sites (it is
important to bear in mind that Tyr
813 must be autopho-
sphorylated in order for SH2-Bb to bind; see Figure S2B,
Supporting Information). Likewise, there are intracellular condi-
tions in which the clamping function would have no apparent
effect; as implied above, saturation of constitutive Jak2-receptor
binding renders the mechanism unnecessary. As we have found for
other proteins with multiple binding domains, there is a clear
indication that the function of SH2-Bb, and even the dominant
mechanism by which it functions, is context-dependent.
Finally, we speculate that the bipolar clamp mechanism studied
here for the Jak2/SH2-B system will be applicable to analogous
signal transduction processes. A striking example is that of 14-3-3
proteins [31]. Like proteins of the SH2-B/APS family, 14-3-3
proteins lack catalytic function, they homo- and hetero-dimerize,
and they simultaneously engage certain phosphorylated proteins
(on phospho-serine/-threonine rather than phospho-tyrosine).
Indeed, 14-3-3 proteins are thought to promote the formation of
complexes containing two isoforms of Raf [32], serine/threonine
kinases that function in the most prominently studied of the
mitogen-activated protein kinase cascades. This provides a clue
that functionally similar mechanisms might be at play at multiple
points of signal transmission from the cell surface to the nucleus.
Methods
Base model of GH/GH receptor dynamics
Where applicable, we build upon a previous model of GH/GH
receptor interactions and trafficking [24] and use the same
parameter values for wild-type human GH. Briefly, the GH ligand
concentration [L] is fixed and is an input variable to the model,
and unbound GH receptors (R) are present at a level of 2610
3
molecules/cell initially. Receptor expression is determined by the
ratio of the synthesis rate [Vs=10 (#/cell)/min] and basal
turnover rate constant (kt=0.005 min
21). Ligand-receptor com-
plexes (C) form with site 1 forward rate constant
kf1=0.1 nM
21 min
21 and reverse rate constant kr1=0.15 min
21
and are subject to basal turnover. Receptor dimers (D), which are
competent for signaling, form from C and R with site 2 forward
rate constant kx2=2.42610
23 (#/cell)
21min
21 and reverse rate
constant k2x2=0.016 min
21, and they can also dissociate via the
site 1 linkage with rate constant 1.5610
23 min
21 (as noted
previously, setting this rate equal to zero does not affect the results
for wild-type human GH), leaving the ligand to dissociate rapidly
via the unstable site 2 linkage. Dimers are endocytosed and
degraded at an enhanced rate, with rate constant ke=0.1 min
21.
Secondary effects of Jak2 and SH2-Bb interactions on GH/GH
receptor dynamics are discussed below.
Intracellular interactions: General considerations
Our models are based on mass-action kinetics, with bimolecular
(association of two species) and unimolecular (dissociation or
change in state of a complex) transitions. Definitions and ranges of
values for the model parameters are given in Table S1 (Supporting
Information). For all bimolecular interactions where one or both of
the species is in the cytosol, the association rate constant kon was
assigned a typical value of 0.06 nM
21 min
21 (or 1.0 mM
21 s
21)
[33], and the dissociation rate constant koff is calculated from
koff=kon KD, where KD is the specified equilibrium dissociation
constant. The total intracellular concentrations of Jak2, SH2-Bb,
and phosphoinositide (JTot, STot, and PTot, respectively) are
conserved and are specified alternatively in units of molar
concentration or molecules/cell; these units are interconverted
by assuming a volume of 0.52 pL, equivalent to that of a sphere
with 5 mm radius.
Jak2 phosphorylation
Jak2 binds receptors, regardless of their ligand-bound status and
the phosphorylation status of Jak2, with a KD defined as KD,RJ. The
model considers phosphorylation of two Jak2 tyrosine sites, Y1 and
Y2, corresponding to Tyr
813 and Tyr
1007, which are responsible
for SH2-Bb association and stimulated activation of Jak2 kinase
activity, respectively. Consistent with the current understanding of
GH receptor activation, Jak2 can be phosphorylated on Y1 and
Y2 only when two Jak2 molecules are associated with the same
complex (receptor or/and SH2-Bb mediated). Once Y2 is
phosphorylated, the catalytic efficiency of that Jak2 molecule
increases substantially. Accordingly, we model Jak2 phosphoryla-
tion as a pseudo-first order process, and once Y2 of the Jak2
Rule-Based Model of Jak2 Activation
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ylation rate constant towards both Y1 and Y2 of the other Jak2
molecule increases from 6 min
21 (0.1 s
21) to 60 min
21 (1 s
21).
Jak2 dephosphorylation is also modeled as a pseudo-first order
process, with a rate constant of 6 min
21 for both Y1 and Y2;
phosphorylated Y1 that is bound to SH2-Bb is protected from
dephosphorylation.
Interactions involving SH2-Bb
SH2-Bb participates in as many as three interactions, with KD
values defined as follows: its SH2 domain binds to Jak2 molecules
with Y1 phosphorylated (KD,JS), its DD dimerizes (KD,SS), and its
PH domain binds phosphoinositides (KD,SP).
The introduction of SH2-Bb in the system gives rise to
interactions in the plane of the membrane or within a multi-
molecular complex, and these occur at accelerated rates in the
forward direction as compared to the situation where one or both
of the interacting species is in the cytosol. Dissociation of such a
linkage is assumed to occur with the same rate constant as when
one or both of the dissociating components is/are released into the
cytosol.
Interactions between two membrane-associated species arise as
a consequence of SH2-Bb binding to phosphoinositide lipids (PS)
or to receptor-bound Jak2 (RJS, with or without ligand), which can
subsequently form complexes such as PS2P, RJSP, RJS2JR, etc. To
simplify the model in a manner that satisfies detailed balance,
interactions in the membrane are assigned a forward rate constant
that iscalculated asxmkon,w i t hkon=0.06 nM
21 min
21=1.91610
24
(#/cell)
21min
21 and xm defined as a common, dimensionless
enhancement factor; as considered in previous signal transduction
models [34,35], its value is based on a confinement layer (reduced
volume) with 10 nm thickness at the membrane, yielding
xm=[(5mm)/3(10 nm)](10
3 nm/mm)=167. The corresponding dis-
sociation rate constant isassumed to be the sameasfor releaseof one
or both species to the cytoplasm; this assumption could be relaxed if
diffusion limitations were to be considered.
Interactions within a complex (ring closure) include the
association of two SH2-Bb molecules with dangling DDs, as in
the species SJ(RLR)JS, or association of SH2-Bb and Jak2 in the
J(RLR)JS2 complex, for example. Ring closure is a unimolecular
transition with forward rate constant calculated as xrkon, where xr is
the effective concentration of an unbound site within the complex,
assumed to be the same for all such interactions (the notation is
from [35], referring to interactions within a receptor complex). A
conservative value of xr=100 mM was used (see [18] for a detailed
discussion). Ring closure also affects GH binding, because of the
ability of the JS2J heterotetramer to dimerize receptors without
ligand present. Thus, the model accounts for closure of species
such as LRJS2JR via the GH (site 2)/GH receptor linkage; because
GH-induced receptor dimerization normally occurs in the plane of
the membrane, the association rate constant for this ring closure
transition is calculated as (xr/xm)kx2.
To avoid the formation of potentially infinite chains at the
membrane, which would occur if GH/GH receptor dimers were
clustered via JS2J linkages (which would be a rare occurrence if
accounted for), the model is constrained so that complexes may
contain no more than 2 receptor molecules. All complexes
containing 2 receptors, whether they contain ligand or not, are
considered receptor dimers and are subject to enhanced
endocytosis, with rate constant ke=0.1 min
21. Internalized
receptors cannot associate with Jak2; any Jak2 and SH2-Bb in
complex with a receptor when it is internalized (whether
endocytosed by the induced or basal turnover pathway) dissociate
at the normal rate.
Specific model cases and rule-based model
implementation
Our simplest model is the so-called In Vitro Model, which
contains only Jak2 and SH2-Bb molecules, and therefore the
largest complex in this model is the heterotetramer, JS2J.I t
considers the best-case scenario where all Y1 sites are pre-
phosphorylated and thus generates only 11 species (state variables)
(Figure 1). The dephosphorylation reactions are turned off in the
In Vitro Model, because phosphatases are not present. The
Simplified Cellular Model considers all of the interactions except
those with phosphoinositides, generating 470 species (5,033
reactions). The Extended Cellular Model adds the influence of
phosphoinositides and generates 2,561 distinct species (41,233
reactions). In variations of this model, we also considered the
influence of a SH2-Bb mutant lacking one or two of its domains,
acting as a dominant negative, alongside the wild-type SH2-Bb
species; these yielded even more species and reactions, according
to the complexity of the dominant negative construct considered:
SH2, 2,849 species; DD, 3,154 species; PH-SH2, 3,152 species;
DD-PH, 3,821 species.
Our rule-based model was developed using the software
program BioNetGen2, which is freely available through http://
bionetgen.org. As discussed in detail elsewhere [17,36], the user
defines the biochemical network in terms of molecules, their
interaction domains, and context-dependent rules for association/
dissociation or covalent modification. Based on those rules, an
exhaustive search is performed to automatically generate all
possible species (combinations of interactions and modification
states) and their corresponding conservation equations (differential
equations in time), which are numerically integrated using a
standard stiff solver up to time=10
3 min, by which time the
system was confirmed to have reached steady state. For the In
Vitro Model, a time of 10 min was used, corresponding to the
experimental conditions. The BNGL files specifying the rules for
the In Vitro, Simplified Cellular, and Extended Cellular models
have been included in the online Supporting Information (Text
S1, Text S2, and Text S3, respectively); note that some of the
parameter values were varied as indicated in the figure legends.
Supporting Information
Figure S1 Jak2 autophosphorylation in vitro without pre-
phosphorylation of the SH2-Bb binding site. Surface and contour
plots of Jak2 autophosphorylation (Y2,P) for varying concentra-
tions and dimerization KD values of SH2-Bb, and with three
different KD values of Jak2/SH2-Bb binding, following the
experimental conditions reported by Nishi et al. Here, unlike the
results presented in Figure 2, the SH2-Bb binding site (Y1) is not
pre-phosphorylated. Rather, Jak2 is allowed to dimerize in the
absence of SH2-Bb (with kon=1mM
21 s
21 and KD=koff/
kon=100 nM), which must happen if Y1 is to be phosphorylated.
Under these conditions, SH2-Bb has very little effect (note the
scale of the z-axis); if Y1 has been phosphorylated, it is likely that
Y2 has been phosphorylated as well, in which case SH2-Bb
binding has no bearing on the Jak2 phosphorylation status of that
complex.
Found at: doi:10.1371/journal.pcbi.1000364.s001 (0.20 MB PDF)
Figure S2 Considering the enhancement of Jak2 catalytic
activity by SH2-Bb binding. Calculations were performed using
the Simplified Cellular Model as outlined under Figure 3, except
an additional effect was added: Jak2 with SH2-Bb bound was
assumed to have 10-fold higher catalytic activity towards other
Jak2 molecules in the same complex. Note here that the absence of
SH2-Bb (SH2-B null) and the inability of SH2-Bb to dimerize
Rule-Based Model of Jak2 Activation
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has catalytic rate constants that are 10 times greater than the base
values (i.e., kphos,slow=60 min
21, kphos,fast=600 min
21). Under those
conditions, there is no significant effect on Jak2 phosphorylation
(compare to Figure 3), because the catalytic activity is already high
enough so that two Jak2 molecules remain almost fully
phosphorylated on Y1 and Y2 while in the same receptor
complex. (B) Jak2 without SH2-Bb bound has catalytic rate
constants that are 10 times lower than the base values (i.e.,
kphos,slow=0.6 min
21, kphos,fast=6 min
21). In this case, Jak2 is not
sufficiently phosphorylated on Y1, the SH2-Bb binding site, and
therefore does not enjoy the benefit of SH2-Bb enhancement of
Jak2 catalytic activity.
Found at: doi:10.1371/journal.pcbi.1000364.s002 (0.23 MB PDF)
Table S1 Model parameters.
Found at: doi:10.1371/journal.pcbi.1000364.s003 (0.09 MB PDF)
Text S1 BNGL code for the In Vitro Model
Found at: doi:10.1371/journal.pcbi.1000364.s004 (,1 MB TXT)
Text S2 BNGL code for the Simplified Cellular Model
Found at: doi:10.1371/journal.pcbi.1000364.s005 (0.01 MB
TXT)
Text S3 BNGL code for the Extended Cellular Model
Found at: doi:10.1371/journal.pcbi.1000364.s006 (0.01 MB
TXT)
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